Navigation Links
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
Date:5/6/2008

d net loss per share 28,217,160 24,561,164

Genomic Health, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

As of As of

31-Mar-08 31-Dec-07

(Unaudited) (Audited)

Cash and cash equivalents $14,355 $39,164

Short term investments 51,012 29,196

Accounts receivable, net 6,736 5,089

Prepaid expenses and other current assets 3,095 3,105

Total current assets 75,198 76,554

Property and equipment, net 12,010 10,412

Restricted cash 500 500

Other assets 437 463

Total assets $88,145 $87,929

Accounts payable $1,957 $1,966

Accrued expenses and other current liabilities 8,896 7,616

Deferred revenue 4,624 1,008

Notes payable, short-term 2,665 2,687

Notes payable, long-term 1,380 2,039

Other liabilities 1,409 1,447

Stockholders' equity 67,214 71,166

Total liabilities and stockholders' equity $88,145 $87,929

The condensed consolidated balance sheet at December 31, 2007 has been

derived from the audited consolidated financial statements at that date

included in the Company's Form 10-K for the
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... MN (PRWEB) , ... July 31, 2015 , ... Ralco ... Enrichment Center at the Lyon County Fair to be held August 5-9 in Marshall. ... about where their meals come from and how agriculture impacts their daily lives. This ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Focus on ... Supportive ... Companies, Inc. (NYSE: PRX ) today announced its commitment,to ... of Strativa Pharmaceuticals, its proprietary,specialty pharmaceuticals division. Strativa Pharmaceuticals will ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... of drugs for the treatment of human ... part of the,restructuring, Idenix has amended the ... Tyzeka(R)/Sebivo(R). Per the amended agreement, Idenix,will discontinue ...
... Settlement, NORCROSS, Ga., Sept. 28 ... leader in providing automated instrument-reagent,systems to the ... and Exchange Commission (SEC) has agreed to ... certain,activities involving the company,s Italian subsidiary. ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 2Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 3Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 4Immucor Settles SEC Investigation 2
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... frequently exposed to heavy traffic pollution or smoke from wood ... University of Melbourne led study has found. The study ... of traffic pollution and wood smoke from heaters on middle-aged ... suffer asthma and were exposed to heavy traffic pollution experienced ...
... needs iron to establish and maintain a biofilm in ... proposed to deprive the bacteria of this necessary element. However, ... published in mBio , the online open-access journal of ... of the two types of iron that are available in ...
... to thousands of species of bacteria collectively called the ... existence. The gastrointestinal (GI) tractand the colon in particularis ... bacterial species. But how do these organisms persist and ... due to foods and fluids moving through it? A ...
Cached Biology News:Traffic pollution and wood smoke increases asthma in adults 2Target 2 forms of iron to control cystic fibrosis lung infection 2A home for the microbiome 2A home for the microbiome 3A home for the microbiome 4
... Quixell, manufactured by Stoelting, selects single cells, ... In no time at all, a single ... the keypad...the cell is collected into the ... wells of a microtiter plate. Quixells unique ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Maize microRNA Microarray contains all known ...
... systems integrate the unique quantitative and qualitative ... 3200 Q TRAP LC/MS/MS Systems with the ... software, to provide a rapid solution for ... , , Eliminate extensive sample preparation with ...
Biology Products: